[Anti-tumor immune response in vitro induced by fusion of Tca8113 cells with macrophages].
OBJECTIVE
To evaluate the therapeutic effectiveness of fusion tumor vaccine in tongue cancer treatment.


METHODS
Human macrophages fused with human tongue carcinoma cell line Tca8113 cell. The fusion cells were selected by magnetic cell sorting (MACS) and cultured. The biological properties of fusion cells and anti-tumor immune response in vitro induced by fusions were observed.


RESULTS
In contrast to Tca8113, the fused cells grew significantly slow in vitro. The expression of MHC I, II antigen of the fusion cells which was detected by flow cytometry (FCM) was higher than that of Tca8113. The fused cells significantly increased the proliferation of mixed lymphocyte and induced their cytotoxicity on parental Tca8113.


CONCLUSIONS
The fusion tumor vaccine of macrophages and OSCC cells increase in vitro immunogenicity significantly. This indicates that fusion tumor vaccine could be a new method of anti-tumor immunotherapy, which has important potentials for effective individualized human OSCC vaccine.
Bi
Ying-chun
YC
Department of Stomatology, 91st Hospital of PLA, Jiaozuo Henan 454100, China.
Yang
Lian-jia
LJ
Dong
Shao-zhong
SZ
Fan
Qing-yu
QY
Zhang
Dian-zhong
DZ
D000818:Animals; D019496:Cancer Vaccines / Q000276:immunology*; D002294:Carcinoma, Squamous Cell / Q000276:immunology*; D002459:Cell Fusion; D045744:Cell Line, Tumor; D006649:Histocompatibility Antigens / Q000276:immunology; D006801:Humans; D066298:In Vitro Techniques; D008264:Macrophages / Q000276:immunology*; D051381:Rats; D014062:Tongue Neoplasms / Q000276:immunology*
D019496:Cancer Vaccines; D006649:Histocompatibility Antigens